Telomere length, telomerase activity and telomerase RNA expression during mouse mammary tumor progression. 1998

Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
Department of Pathology II, Kansai Medical University, 10-15 Fumizono, Moriguchi, Osaka 570-8506, Japan.

To investigate the roles of telomere length (mean length of the terminal restriction fragments; TRFs), telomerase activity (TA) and telomerase RNA (mTR) expression in relation to mouse mammary tumor progression, we examined a pregnancy-dependent mouse mammary tumor line (TPDMT-4) and its four autonomous sublines (T4-OI320: non-metastatic; and T4-OI165, -OI96, and -OI145: artificial metastatic) of DDD/1 mouse origin, and an autonomous growing mammary tumor (JYG-MC) showing spontaneous lung metastasis developed in BALB/c mice infected with a Chinese feral mice (Sub-Jyg)-derived mouse mammary tumor virus (JYG-MTV). Compared with normal (pregnant) mammary tissue, the TA was elevated in the TPDMT-4 tumor and in the non-metastatic subline tumor (T4-OI320) (x10 fold, respectively), and was further increased (x13-15 fold) in parallel with the acquisition of metastatic potential (T4-OI165, -OI96, and -OI145). The mTR level was upregulated (x2.7-2.8 fold) in all autonomous growing tumors compared to the normal counter-part, but not in TPDMT-4. The TRF was shorter in accord with tumor progression (normal mammary tissue, 48 kb; TPDMT-4, 45 kb; T4-OI320, 37 kb; T4-OI165, -OI96 and -OI145, mean 37.7 kb; and JYG-MC, 21 kb). These results suggest that the activation of TA occurs as an early event at the stage of hormone-dependent tumorigenesis, followed by the up-regulation of mTR expression in accordance with the acquisition of autonomous growth, and then further activation of TA occurs when the tumor acquires metastatic potential. The TRF shortening was in parallel with the tumor progression.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008321 Mammary Glands, Animal MAMMARY GLANDS in the non-human MAMMALS. Mammae,Udder,Animal Mammary Glands,Animal Mammary Gland,Mammary Gland, Animal,Udders
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D009376 Neoplasms, Hormone-Dependent Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. Hormone-Dependent Neoplasms,Hormone Dependent Neoplasms,Hormone-Dependent Neoplasm,Neoplasm, Hormone-Dependent,Neoplasms, Hormone Dependent
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011252 Pregnancy Complications, Neoplastic The co-occurrence of pregnancy and NEOPLASMS. The neoplastic disease may precede or follow FERTILIZATION. Complications, Neoplastic Pregnancy,Neoplastic Pregnancy Complications,Pregnancy, Neoplastic Complications,Complication, Neoplastic Pregnancy,Neoplastic Pregnancy Complication,Pregnancies, Neoplastic Complications,Pregnancy Complication, Neoplastic
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D016615 Telomere A terminal section of a chromosome which has a specialized structure and which is involved in chromosomal replication and stability. Its length is believed to be a few hundred base pairs. Telomeres

Related Publications

Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
October 1997, Biochemical and biophysical research communications,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
October 2001, American journal of veterinary research,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
December 2018, The Journal of reproduction and development,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
October 1997, Cell,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
June 2015, Anticancer research,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
September 2004, Current protocols in immunology,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
January 2015, PloS one,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
January 2015, Advances in gerontology = Uspekhi gerontologii,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
January 2005, Methods in molecular medicine,
Y Kiyozuka, and A Asai, and H Senzaki, and Y Uemura, and A Nakashima, and J Morimoto, and A Matsuzawa, and A Tsubura
January 2000, Anticancer research,
Copied contents to your clipboard!